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Point-of-care viral load tests are being developed to monitor patients on antiretroviral therapy (ART) in sub-Saharan Africa. Test
design involves trade-offs between test attributes, including accuracy, complexity, robustness, and cost. We used a model of the
human immunodeﬁciency virus epidemic and ART program in Zimbabwe and found that the attributes of a viral load testing ap-
proach that are most inﬂuential for cost effectiveness are avoidance of a high proportion of failed tests or results not received, use of
an approach that best facilitates retention on ART, and the ability to facilitate greater use of differentiated care, including through
expanding coverage of testing availability.
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Since 2013, the World Health Organization (WHO) recom-
mended viral load as the preferred approach for monitoring
patients on antiretroviral therapy (ART) [1]. Although in high-
income countries tests are done on plasma samples obtained
by venipuncture, in low-income settings a more realistic option,
particularly for more rural areas, is the use of dried blood spots
(DBS), which are relatively easy to collect and can be transport-
ed to regional laboratories in stable condition [1, 2]. The intent
is to receive the results at the clinic within a few weeks and then
provide appropriate treatment at the patient’s next visit to the
clinic. Although this approach is increasingly being adopted
[3], there remains interest in development of tests that require
minimal user training and can be performed in the clinic
while a patient is present (ie, at point of care [POC]) [4–7].
Several attributes need to be considered when designing such
tests, including accuracy, whether the format allows easy use
by lower cadres of staff, and in locations that do not have a
reliable electricity supply. Developers must balance trade-offs
between these attributes and with the cost at which a test can
be produced. In this study, we use a modeling approach to ex-
plore the impacts of different test attributes on cost effectiveness
and target test costs. This builds upon previous work on POC
viral load tests in relation to the use of DBS [8]).
METHODS
We use an existing individual-based stochastic model of hetero-
sexual transmission, progression, and treatment of human im-
munodeﬁciency virus (HIV) infection, which incorporates
treatment adherence and acquisition and transmission of drug
resistance mutations [8] (Supplementary Material). The epi-
demic and ART program data simulated relate to Zimbabwe
(Supplementary Table 1, Figure 1). We assumed that CD4
count monitoring was used before 2017 and that viral load
monitoring using the WHO-recommended 1000 cps/mL
threshold for switching is then introduced. Measurement of
viral load ≥1000 cps/mL prompts enhanced adherence support
with a follow-up measure taken after 3 months. A measured
viral load <1000 cps/mL in the past year is assumed to lead to
a reduction in non-ART programmatic costs due to lowered fre-
quency of clinic visits in people on ﬁrst-line ART (ie, viral load-
informed differentiated care [8]).
A range of attributes relating to the viral load testing ap-
proach were considered, and these are outlined in Table 1.
We ﬁrst simulated outcomes over the years 2017–2036 based
on a set of viral load testing attributes that were considered to
approximate the use of a DBS approach and the current situa-
tion in Zimbabwe (“base DBS scenario”) (Table 1). We then
explored the effects of changes in the attribute values, one-
by-one, on population health. Population health is measured
using disability-adjusted life years (DALYs) incurred; a generic
measure of the burden of disease in the population that
captures both premature mortality and morbidity as a result
of ill health.
In the DBS base scenario, it is assumed that 75% of the pop-
ulation have access to viral load testing, whereas the remainder
would continue to be monitored using CD4 count testing. In
Received 6 April 2016; accepted 25 July 2016.
Correspondence: A. Phillips, Department of Infection & Population Health, UCL, Royal Free
Campus, Rowland Hill Street, London NW3 2PF, United Kingdom (andrew.phillips@ucl.ac.uk).
Open Forum Infectious Diseases®
© The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the work
is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/ofid/ofw161
Modeling Point-of-Care Viral Load Testing • OFID • 1
Figure 1. (A) Comparison of health outcomes according to individual attributes of the viral load testing approach, shown as the difference in disability-adjusted life years
(DALYs) incurred compared with dried blood spots (DBS) base scenario. The influence of the attribute is indicated by the range in difference in DALYs incurred for plausible
values of the attribute. The DALYS are per 3 months over 20 years from 2017, discounted at 3% per year. (B) Comparison of cost effectiveness according to individual attributes
of the viral load testing approach, shown as the difference in net DALYs compared with DBS base scenario. The influence of the attribute is indicated by the range in difference
in net DALYs for plausible values of the attribute. ART, antiretroviral therapy.
2 • OFID • Phillips et al
previous modeling results, DALY outcomes from monitoring
the CD4 count using a switch criteria based on a threshold of
200 cells/mm3 were not appreciably different from monitoring
with viral load [8]. In this study, to capture the intended effects
of viral load testing, we assume a relatively high rate of switch to
second-line ART when the failure criteria have been met with
viral load monitoring (0.2 per 3 months), which is greater
than the 0.001 per 3 months with CD4 count monitoring
(based on the low number of people on second-line ART).
Economic Considerations
Program costs resulting from different viral load testing attri-
butes were also considered, enabling assessment of cost-effec-
tiveness on the basis of net DALYs. This is a measure
analogous to net health beneﬁt [16] and compares the health
gains from an intervention with the health losses associated
with displaced or forgone intervention that can no longer be
provided due to the commitment of limited healthcare resourc-
es to the evaluated intervention (ie, it compares health gains to
health opportunity costs). The cost-effectiveness threshold
(CET) is central to the estimation of net DALYs—it is an esti-
mate of the cost per DALY averted of interventions displaced/
foregone at the margin when a new intervention in introduced
[17]. Net DALYs is then calculated as DALYs + costs/CET. For
most healthcare systems, the CET is generally not readily appar-
ent, but a value of $500 per DALY averted is thought to be re-
alistic for low-income settings in sub-Saharan Africa because
alternative policy interventions (eg, expanded ART provision)
offer health gains at about this level [18]. The testing policy
with the lowest net DALYs is deemed the cost-effective policy
Table 1. Key Attributes of a Viral Load Testing Approach and Values for Attributes Considered
Attribute of Viral Load Testing Approach
Value in Base
Scenario (Using
DBS)
Other Values
Considered Comment
(1) Delay in result 3 mo delay No delay By definition, any delay will be avoided with a POC test, and
therefore the result will be available at the same visit.
(2) Sensitivity/specificity relative to plasma for
1000 copies/mL cutoff
84%/89% 58/96 84/89 If a plasma sample is used for a POC test, then the accuracy of the
test could be higher than for DBS. In calibrating any test, it is
useful to know whether to prioritize sensitivity or specificity.
60/99 89/93
69/97 90/85
70/79 95/90
74/75 96/65
78/93 96/77
79/71 99/69
80/84 100/100
82/96
(3) VL threshold used to define first-line ART
failure (cutoff for qualitative or
semiquantitative assays)
1000 copies/mL 200, 500, 3000, 5000 WHO failure threshold is 1000 copies/mL. This choice of threshold
is important if a qualitative test is being developed that reads as
positive or negative rather than providing a value.
(4) Proportion of tests failed or result lost 0.15 0.8, 0.5, 0.3, 0 It is likely that most tests that are done using POC will actually be
used because the patient is still present when the result is
received. For DBS, a higher proportion of tests will not get used
due to communication/linkage failures, leading to delay in
informed decision making and wasted costs. We assume that if
a test fails, then it is attempted again after 3 mo.
(5) Probability of differentiated care if
VL < 1000 being implemented
0.8 0.5, 0.6, 0.7, 0.9 POC test should enable VL-informed differentiated care because
the date of a person’s next clinic appointment can be set with
the person present, avoiding the need to call people later to
adjust the timing of their next visit.
(6) Coverage of population with VL testing 75% of population 70%, 80%, 85%,
90%, 95%, 100%
POC tests should enable greater access to (coverage of) VL testing
in a country, because it is an additional option to DBS testing.
(7) Probability of switch to second-line ART
per 3 mo once failure definition met
0.2 per 3 mo 0.05, 0.10, 0.15, 0.25,
0.30, 0.35, 0.40, 0.60,
1.00
It is theoretically possible that a POC test will result in a more rapid
switch, due to the ability to act on VL result while the patient is
present.
(8) Probability of ART interruption/loss to
follow up
0.020 per 3 mo 0.030, 0.025, 0.015,
0.010, 0.005
Given the enabling of VL-informed differentiated care, POC tests
could result in lower rates of disengagement from care, although
this is uncertain and needs to be assessed in studies.
Abbreviations: ART, antiretroviral therapy; DBS, dried blood spots; HIV, human immunodeficiency virus; POC, point of care; VL, viral load; WHO, World Health Organization.
(1) Delaymay be up to 3 months. (2) The sensitivity and specificity are not input parameters: they are outputs that depend on the assumed standard deviation for the measurement variability and
any offset (see SupplementaryMaterial, section 9). Values Informed by overview of various studies comparing VL values on DBS/plasma (eg, [1, 9, 10]). (3) [11]. (4) This is failure due to technical
reasons in the laboratory or failure for results to be successfully returned: the value is likely to vary by setting within countries as well as between countries—the value of 0.15 is a conservative
estimate of what is achievable with a DBS transport network (eg, [12]; F Cowan (oral personal communication, CESHHAR, Zimbabwe, 10 December 2015)). It is not yet certain whether use of
DBS for viral load testing can achieve similar results, because the number of tests to be done will be much higher. (5) Assumption: 0.80 may be rather high for DBS, and data are required to
inform this. (6) Coverage assumed to be 75% in base case: this is closely linked to (4) above, and 75% is conservative for what is feasible for EID; an assumption is made, even for base scenario
DBS, that the probability of switch is higher with viral load monitoring than with CD4 count monitoring (0.001 per 3 months). (7) Differs by setting (eg, [13, 14]). (8) Consistent with [15] (see
details in Supplementary Material). This is base rate of interruption - it is increased within first 2 years of ART and in those with suboptimal lifetime tendency to adhere (see details in
Supplementary Material).
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from amongst those evaluated because it leads to the greatest
reduction in population burden of disease (ie, lowest DALYs).
The opportunity cost of interventions displaced at the mar-
gin, represented by the CET, also informs the price within
which interventions must be delivered to offer population
health improvement and be deemed cost effective. For the
value of each viral load testing attribute, the upper-bound
cost that the viral load test would need to be delivered is provid-
ed. A health system perspective was adopted, and costs incurred
by patients were not included. Both costs and DALYs averted
were discounted to present value using a 3% per annum dis-
count rate.
Unit costs (in US dollars at 2015 prices) are detailed in Sup-
plementary Material. Costs of viral load assays were set at a base
value of $22, based on cost estimates using the DBS approach
and counting all components of delivery (reagents, equipment,
human resources, buildings, set-up costs, etc [referred to as a
“fully-loaded” cost]) (see details in Supplementary Material).
Annual program costs for clinic visits (not including drug or
viral load/CD4 count tests) are $80 per year [19] with an as-
sumed reduction to $40 per year after measurement of viral sup-
pression because of reduced clinical visit frequency within a
differentiated care model [8]. Health utilities and disability
weights to calculate DALYs averted were derived from a recent
comprehensive study [20].
RESULTS
The status of the simulated Zimbabwean adult population in
2014 is shown in Supplementary Table 1. Figure 1A shows
the effect on DALYs incurred over 20 years of differences in at-
tribute values associated with viral load testing. The delay asso-
ciated with DBS testing had a relatively modest inﬂuence on the
number of DALYs incurred. The sensitivity of the test for de-
tecting a value above 1000 cps/mL was more inﬂuential, with
generally higher sensitivity leading to a lower number of
DALYs incurred, regardless of speciﬁcity and due to enhanced
adherence support and switching to second-line ART in those
who require this. When the sensitivity was approximately 90%
or above, then a lower speciﬁcity was associated with a lower
number of DALYs incurred, reﬂecting that those with viral
loads between 50 and 1000 copies/mL may also beneﬁt from a
switch to second-line ART. The viral load threshold used is also
moderately inﬂuential, with more DALYs averted the lower the
threshold. The proportion of tests that fail or the results lost was
also inﬂuential, due to the inability to act on viral load failure in
a timely way or at all. The probability that viral load-informed
differentiated care was implemented did not inﬂuence the
DALYs, because we did not assume any positive or negative
health effects of such a policy, only an impact on costs. The
rate of switch to second-line ART in people with ﬁrst-line fail-
ure is also inﬂuential on DALYs incurred. It is uncertain wheth-
er the viral load testing format (laboratory based or POC) will
inﬂuence this parameter, although it is plausible that if the re-
sult is available while the patient is present, then a switch is
more likely to be instigated compared with a laboratory result
that is only available on a return visit. The extent to which a
test can result in increased coverage of viral load positively in-
ﬂuenced the DALY outcome, mostly through the assumed
greater rate of switch to second-line ART where viral load test-
ing is used. The rate of ART interruption or loss to follow-up is
highly inﬂuential, although, again, it is uncertain whether the
form of viral load testing will inﬂuence this parameter.
In Figure 1B, we considered the inﬂuence of each factor on
the net DALYs, which takes into account the opportunity
costs of differences in cost in addition to the DALYs incurred.
The relative inﬂuence of the various factors was similar to
Figure 1A, with a few exceptions. Lower speciﬁcity was associated
with higher net DALYs, due to the additional cost of second-
line drugs, and a sensitivity and speciﬁcity of approximately
90% was close to the that with 100% sensitivity and speciﬁcity.
The viral load threshold to deﬁne ART failure was less inﬂuen-
tial on net DALYs than it was on DALYs, because use of higher
thresholds reduced costs. The proportion of tests that fail or are
lost was even more inﬂuential on net DALYs than on DALYs,
due to the cost incurred with repeated attempts to successfully
measure viral load. The probability of implementing viral load-
informed differentiated care was also inﬂuential, due to the cost
savings for clinic. The probability of switching to second-line
ART once the failure criteria were met was less inﬂuential on
net DALYs than on DALYs, again due to the higher costs of sec-
ond-line ART.
In Table 2, for each level of each viral load testing attribute,
we provided the upper-bound cost for a POC test to be consid-
ered as cost effective compared with the DBS base scenario. For
example, if a POC test demonstrated an increase in the proba-
bility of viral load-informed differentiated care from 0.8 to 0.9,
then, with no other difference compared with the DBS base sce-
nario, it could cost $24 and still be cost effective compared with
the DBS base scenario with the $22 test cost. Alternatively, if a
POC test demonstrated a halving of the rate of ART interrup-
tion or loss to follow-up compared with the DBS approach, with
no other difference compared with the DBS base scenario, then
it would be cost effective up to a cost of $41 per test. Further-
more, if the approach resulted in 100% coverage, then a test
could cost up to $28 and remain cost effective; that is, if the
test replaced the $22 test in all. If the tests were used to ﬁll
the coverage “gap”, then it could cost much more, while pre-
serving the same overall cost of viral load testing, and remain
cost effective.
DISCUSSION
Our results indicate that the attributes of a viral load testing ap-
proach most inﬂuential for cost effectiveness are avoidance of a
high proportion of failed tests or results not being received and,
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so far as it can be inﬂuenced by the viral load monitoring strat-
egy, use of an approach that best facilitates retention on ART.
Also of particular importance was the ability to facilitate greater
use of differentiated care through expanding coverage of
Table 2. Maximum Cost of Viral Load Test for Net Health Benefit in the Context of Changes in Values of Each Attribute of the Viral Load Testing Approach,
Changing the Value of Only One Attribute at a Time
Attribute of Viral Load Testing
Approach
Values for Factor Considered Maximum Fully Loaded Cost of
Viral Load Test for Reduced Net
DALYs Compared With Base
Scenario
(1) Delay in result No delay $23
3 mo delaya $22
(2) Sensitivity/specificity relative
to plasma for 1000 copies/mL
cutoff
Sensitivity/Specificity
58/96 84/89a $21 $22
60/99 89/93 $20 $21
69/97 90/85 $20 $22
70/79 95/90 $19 $21
74/75 96/65 $17 $15
78/93 96/77 $20 $17
79/71 99/69 $15 $20
80/84 100/100 $19 $23
82/96 $21
(3) VL threshold used to define
first-line ART failure (copies/
mL) (cutoff for qualitative
assay)
200 $20
500 $23
1000a $22
3000 $19
5000 $19
(4) Proportion of tests failed or
result lostb
0.80 $5
0.50 $16
0.30 $19
0.15a $22
0.00 $24
(5) Probability of differentiated
care if VL < 1000 being
implemented
0.5 $14
0.6 $16
0.7 $19
0.8a $22
0.9 $24
(6) Difference in coverage of
population with VL testing
70% $20
75%a $22
80% $23
85% $25
90% $26
95% $26
100% $28
(7) Probability of switch to
second-line ART per 3 mo once
failure definition met
0.05 $17
0.10 $20
0.15 $20
0.20a $22
0.25 $22
0.30 $23
0.40 $23
0.60 $23
1.00 $25
(8) Probability of ART interruption/
loss to follow up (per 3 mo)
0.030 $3
0.025 $14
0.020a $22
0.015 $29
0.010 $41
0.005 $48
Abbreviations: ART, antiretroviral therapy; DALYs, disability adjusted life years; VL, viral load.
a Base scenario (VL cost $22).
b Assumed that there is a 90% chance that the cost of the test is nevertheless incurred.
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availability of viral load testing. These attributes are most likely
to be found with a robust POC viral load test that facilitates
decision making while the patient is present. It is noteworthy
that a 3-month delay in receiving a result does not result in a
signiﬁcant negative impact, and also that sensitivity and specif-
icity both in the region of 90% appear to be acceptable. Due to
the higher cost of second-line drugs, the inﬂuence of the
switching rate in those with ﬁrst-line ART failure was not
one of the most important attributes for cost effectiveness.
Our results emphasize the need for POC viral load tests and
may inform the development of tests as well as the design of
future implementation studies and trials on viral load testing
approaches. Our results suggest that it is important for studies
to consider how POC viral load testing impacts the patient care
model, such as earlier switch to second-line drugs or better re-
tention in care. Whether these factors are indeed improved
with POC testing will have to be evaluated in implementation
studies, and data could then be used to inform our cost-effec-
tiveness modeling. It may prove to be important, for example,
that the waiting time to receive a result from a POC assay is as
low as possible.
Several POC viral load assays have already been developed
(eg, by Cepheid, Liat, and Alere), and some pilot studies have
been completed. Many of these assays already meet high levels
of accuracy, but our results indicate that perhaps other param-
eters (such as potential coverage and assay costs) still need to be
prioritized.
The WHO has established the ASSURED (affordable, sensi-
tive, speciﬁc, user-friendly, rapid/robust, equipment-free and
deliverable to end-users) criteria for POC diagnostics [21]. It
has been suggested that the WHO preference for equipment-
free POC tests presents a potential conﬂict with the need to de-
liver high sensitivity and speciﬁcity [22].Our results suggest that
the population health effects of reduced sensitivity and speciﬁc-
ity, of an equivalent level to the DBS base scenario, for example,
are modest compared with the potential beneﬁts of increased
access and ease of patient management. Weidemaier et al [16]
argue that ASSURED criteria imply that resource capacities for
where interventions are ultimately to be used should be taken
into consideration throughout the technology development
process. This study attempts to facilitate this for POC viral
load tests.
We assigned a set of attribute values to the DBS base scenario,
but there remains uncertainty whether these can be achieved
in practice. We considered compiling 1 or 2 plausible sets of
attributes that might reﬂect a particular POC test. We elected
not to do this because any given choice of parameter sets
seems extremely arbitrary. There are no data available on real-
life implementation of true POC assays to inform the values. As
data become available on attributes of different testing
approaches, our model can be used to compare cost effective-
ness both between POC tests and with the DBS alternative.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
Acknowledgments
Author Contributions. All authors contributed to deﬁning the analysis
concept and design, providing critical input to the conduct of the modeling
analysis, and writing the manuscript. A. P., V. C., and F. N. developed the
model and conducted the modeling analysis.
Financial support. This work was funded by the Bill & Melinda Gates
Foundation grant number OPP1064862. We thank colleagues supporting
the Legion computing cluster (Legion@UCL) for critical computing support.
Potential conﬂicts of interest. A. P. reports grants from the Bill &
Melinda Gates Foundation, during the conduct of the study; and personal
fees from Gilead Sciences, Abbvie, GSK Biologicals, and Ashﬁeld Communi-
cations, outside the submitted work. All authors have submitted the ICMJE
Form for Disclosure of Potential Conﬂicts of Interest. Conﬂicts that the edi-
tors consider relevant to the content of the manuscript have been disclosed.
References
1. World Health Organization. Technical and operational considerations for imple-
menting HIV viral load testing. Available at: http://www.who.int/hiv/pub/arv/
viral-load-testing-technical-update/en/. Accessed 14 August 2016.
2. Smit PW, Sollis KA, Fiscus S, et al. Systematic review of the use of dried blood
spots for monitoring HIV viral load and for early infant diagnosis. PLoS One
2014; 9:e86461.
3. Ministry of Health & Child Care. Operational and Service Delivery Manual for the
Prevention, Care and Treatment of HIV in Zimbabwe AIDS & TB Programme.
Zimbabwe, 2015. http://www.differentiatedcare.org/Portals/0/adam/Content/
hc5QvbYtZUSXdE-1M-pxcQ/File/Operational%20And%20Service%20Delivery%
20Manual%20(6).pdf.
4. Rowley CF. Developments in CD4 and viral load monitoring in resource-limited
settings. Clin Infect Dis 2014; 58:407–12.
5. Shaﬁee H, Wang SQ, Inci F, et al. Emerging technologies for point-of-care man-
agement of HIV infection. Annu Rev Med 2015; 66:387–405.
6. Stevens W, Gous N, Ford N, Scott LE. Feasibility of HIV point-of-care tests for
resource-limited settings: challenges and solutions. BMC Med 2014; 12:173.
doi:10.1186/s12916-014-0173-7.
7. UNITAID. HIV/AIDS Diagnostics Technology Landscape. Semi-annual update.
2015. Available at: http://www.aidsdatahub.org/hivaids-diagnostics-technology-
landscape-semi-annual-update-murtagh-mm-2015. Accessed 14 August 2016.
8. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in
Sub-Saharan Africa. Sustainable HIV treatment in Africa through viral-load-in-
formed differentiated care. Nature 2015; 528:S68–76.
9. Mavedzenge SN, Davey C, Chirenje T, et al. Finger prick dried blood spots for HIV
viral load measurement in ﬁeld conditions in Zimbabwe. PloS ONE 2015; 10:
e0126878.
10. Smit PW, Sollis KA, Fiscus S, et al. Systematic review of the use of dried blood
spots for monitoring HIV viral load and for early infant diagnosis. PLoS ONE
2014; 9:e86461.
11. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and
preventing HIV infection: recommendations for a public health approach. Geneva:
World Health Organization, 2013. Available at: http://www.who.int/hiv/pub/
guidelines/arv2013/en/. Accessed 1 september 2016.
12. Chatterjee A, Tripathi S, Gass R, et al. Implementing services for Early Infant Di-
agnosis (EID) of HIV: a comparative descriptive analysis of national programs in
four countries. BMC Public Health 2011; 11:553.
13. Johnston V, Fielding K, Charalambous S, Churchyard G, Phillips AN, Grant A. Out-
comes following virological failure and predictors of switching to second-line antire-
troviral therapy in a South African treatment program JAIDS 2012;61:370–80.
14. Fox MP, van Cutsem G, Giddy J, et al. Rates and predictors of failure of ﬁrst-line
antiretroviral therapy and switch to second-line ART in South Africa. JAIDS 2012;
60:428–37
15. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy
in clinical practice: a systematic review. Tropical Medicine and International
Health 2011; 16: 1297–313.
16. Stinnett AA, Mullahy J. Net health beneﬁts a new framework for the analysis of
uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18(2 Suppl):
S68–80.
17. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate Perspectives for Health
Care Decisions, Centre for Health Economics. Research Paper 54, University of
York. 2010.
6 • OFID • Phillips et al
18. Woods E, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresh-
olds: Initial Estimates and the Need for Further Research, March 2015. Available at:
https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP109_
cost-effectiveness_threshold_LMICs.pdf. Accessed 14 August 2016.
19. Tagar E, Sundaram M, Condliffe K, et al. Multi-country analysis of
treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis
in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS One 2014; 9:
e108304.
20. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health out-
comes from disease and injury: disability weights measurement study for
the Global Burden of Disease Study 2010. Lancet 2012; 380:2129–4310.
21. Kettler H, White K, Hawkes S. Mapping the landscape of diagnostics for sexually
transmitted infections, 2004. Available at: http://www.who.int/tdr/publications/
documents/mapping-landscape-sti.pdf. Accessed 15 August 2016.
22. Weidemaier K, Carrino J, Curry A, et al. Advancing rapid point-of-care viral di-
agnostics to a clinical setting. Future Virology 2015; 10:313–28.
Modeling Point-of-Care Viral Load Testing • OFID • 7
